iwMyeloma 2022 | T-Cell Engagers: targets, challenges and opportunity
Immunotherapy has revolutionized the hematological-oncology space, with response rates that would have been unimaginable just a few years ago. The myeloma community is pathing the way in the CAR-T cell therapy space, as is discussed by the experts in this session. The speakers debate the future place of T-cell engagers in the myeloma treatment algorithm, the role of maintenance and transplantation, the use of multiple antigens, and target antigen loss. Additionally, the challenges patients with extramedullary disease pose, allogeneic CAR-T cells and the potential of NK cells. Hermann Einsele, MD, FRCP, of University of Würzburg, Würzburg, Germany, chairs this session with Nina Shah, MD, University of California, San Francisco, CA, and Thomas Martin, MD, University of California, San Francisco, CA. This discussion took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
